TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04216342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fx-5A peptide complex
Description: subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
Study: NCT06317662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT05152849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXA1125
Description: AXA1125 administered BID with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered BID with or without food
Study: NCT05941715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 40 MG/ML
Description: treat-and-extend

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab 120 MG/ML
Description: treat-and-extend

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab 120 MG/ML
Description: treat-and-extend
Study: NCT06317662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study: NCT01140100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiopental,propofol
Study: NCT05626322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral (by mouth)
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study: NCT05626322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral (by mouth)
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05185245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
Study: NCT05146297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical trial match-list
Description: Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Match-list intervention
Description: Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
Study: NCT05612373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study: NCT04868994

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body MRI and ENMG
Description: Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03981757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurOS
Description: NeurOS system pads will be placed on patients' head for monitoring.
Study: NCT06166459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon combined with provisional drug-eluting stent implantation
Description: (1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study: NCT06208293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KPZ Program (KPZ)
Description: The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
Study: NCT04823923

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
Study: NCT05422495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training with Cycléo device (COTTOS ®),
Description: 8 weeks of training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non intervention
Description: non intervention
Study: NCT06317662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or NG or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT05984186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Therapy
Description: FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Therapy
Description: FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Therapy
Description: FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Therapy
Description: FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
Study: NCT05342012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Description: Acute and chronic supplementation of beetroot juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Description: Acute and chronic supplementation of beetroot juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate depleted beetroot juice
Description: (Nitrate depleted beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate depleted beetroot juice
Description: (Nitrate depleted beetroot juice
Study: NCT05867420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG915
Description: ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
Study: NCT05847660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone antagonist
Description: Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional antagonist protocol
Description: Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
Study: NCT04989816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Study: NCT05180838

Intervention type: DEVICE
Intervention: BioSticker
Description: The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
Study: NCT04798261

Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System
Study: NCT06513507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabigerol (CBG)
Description: The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Study: NCT05730829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain informed movement
Description: group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard neuromuscular exercise
Description: group classes twice weekly for 8 weeks of neuromuscular exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard osteoarthritis (OA) education
Description: The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
Study: NCT06642571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 B
Description: NNC0519-0130 B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 B
Description: NNC0519-0130 B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 B
Description: NNC0519-0130 B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 B
Description: NNC0519-0130 B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 C
Description: NNC0519-0130 C will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 C
Description: NNC0519-0130 C will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 C
Description: NNC0519-0130 C will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130 C
Description: NNC0519-0130 C will be administered subcutaneously.
Study: NCT05562427

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gold-Standard Online Behavioral Obesity Treatment
Description: Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
Study: NCT04905797

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Stop Signal Task
Description: Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Stop Signal Task
Description: Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Stop Signal Task
Description: Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Stop Signal Task
Description: Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
Study: NCT06056713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Massage
Description: The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
Study: NCT05533281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tropisetron
Description: One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.